Singh Jitendra, Kumar Nilesh, Dinkar Anju
Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, U.P, India.
Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, U.P, India.
Infect Disord Drug Targets. 2022;22(7):27-38. doi: 10.2174/1871526522666220429134113.
SARS-CoV-2 infection typically presents with fever and respiratory symptoms. Besides this, COVID-19-related central and peripheral nervous system manifestations are emerging.
This study summarises the demographics, clinical profiles, laboratory findings, management strategies, and outcomes in a large number of patients with COVID-19-related GBS and its variants. We also compared its clinical profile with Zika and dengue virus-related GBS.
The authors carried out a literature search up to Dec 31, 2020, in MEDLINE, PubMed, SCOPUS, Cochrane database, and Google Scholar for all published articles.
The study identified 54 different types of articles consisting of 70 cases from 17 countries worldwide. A maximum of 15 cases (21.4 %) were identified from Italy, followed by the USA (12; 17.1 %), Spain (11; 15.7 %), and Iran (10; 14.3 %). The age group that was more than 60 years had the most cases, i.e., 32 (45.7 %), followed by the age group 40-60 with 25 cases (35.7 %) with a male to female ratio of 2. Maximum cases were treated with IVIG infusion 58 (82.9 %), followed by Plasma exchange 13 (18.6 %) cases. Out of 70 cases, 7 (10 %) cases were manifested as Miller-Fisher syndrome. The most predominant electrodiagnostic variant was demyelinating neuropathy in 41 (73.21 %) cases. The outcome reported in 67 cases was survival in 63 (90 %) cases and death in 4 (5.7 %) cases.
Covid-19-related GBS were reported worldwide with a better outcome. Both postinfectious and parainfectious patterns were reported. Early recognition with prompt management of GBS can prevent further severe morbidity and mortality.
新型冠状病毒2型（SARS-CoV-2）感染通常表现为发热和呼吸道症状。除此之外，新型冠状病毒肺炎（COVID-19）相关的中枢和外周神经系统表现也不断出现。
本研究总结了大量COVID-19相关吉兰-巴雷综合征（GBS）及其变异型患者的人口统计学特征、临床概况、实验室检查结果、管理策略和预后。我们还将其临床特征与寨卡病毒和登革热病毒相关的GBS进行了比较。
作者在MEDLINE、PubMed、SCOPUS、Cochrane数据库和谷歌学术上检索了截至2020年12月31日所有已发表的文章。
该研究共识别出54种不同类型的文章，涵盖了来自全球17个国家的70例病例。其中，意大利最多，有15例（21.4%），其次是美国（12例；17.1%）、西班牙（11例；15.7%）和伊朗（10例；14.3%）。60岁以上年龄组的病例最多，为32例（45.7%），其次是40 - 60岁年龄组，有25例（35.7%），男女比例为2。大多数病例接受静脉注射免疫球蛋白（IVIG）治疗，共58例（82.9%），其次是血浆置换，共13例（18.6%）。在70例病例中，7例（10%）表现为米勒-费希尔综合征。最主要的电诊断变异型是脱髓鞘性神经病，共41例（73.21%）。67例病例的预后报告显示，63例（90%）存活，4例（5.7%）死亡。
全球均有COVID-19相关GBS的报道，预后较好。报告了感染后和感染旁两种模式。早期识别并及时管理GBS可预防进一步的严重发病和死亡。
